Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice by O'Riordan, C. E. et al.
ORIGINAL RESEARCH
published: 06 September 2019
doi: 10.3389/fimmu.2019.02129
Frontiers in Immunology | www.frontiersin.org 1 September 2019 | Volume 10 | Article 2129
Edited by:
Rudolf Lucas,
Augusta University, United States
Reviewed by:
Basilia Zingarelli,
Cincinnati Children’s Hospital Medical
Center, United States
Helder Mota-Filipe,
University of Lisbon, Portugal
*Correspondence:
Caroline E. O’Riordan
c.e.oriordan@qmul.ac.uk
Christoph Thiemermann
c.thiemermann@qmul.ac.uk
Specialty section:
This article was submitted to
Inflammation,
a section of the journal
Frontiers in Immunology
Received: 10 April 2019
Accepted: 23 August 2019
Published: 06 September 2019
Citation:
O’Riordan CE, Purvis GSD, Collotta D,
Chiazza F, Wissuwa B, Al Zoubi S,
Stiehler L, Martin L, Coldewey SM,
Collino M and Thiemermann C (2019)
Bruton’s Tyrosine Kinase Inhibition
Attenuates the Cardiac Dysfunction
Caused by Cecal Ligation and
Puncture in Mice.
Front. Immunol. 10:2129.
doi: 10.3389/fimmu.2019.02129
Bruton’s Tyrosine Kinase Inhibition
Attenuates the Cardiac Dysfunction
Caused by Cecal Ligation and
Puncture in Mice
Caroline E. O’Riordan 1*, Gareth S. D. Purvis 1, Debora Collotta 2, Fausto Chiazza 2,
Bianka Wissuwa 3,4, Sura Al Zoubi 1, Lara Stiehler 1,5, Lukas Martin 1,5, Sina M. Coldewey 3,4,
Massimo Collino 2 and Christoph Thiemermann 1*
1William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of
London, London, United Kingdom, 2Department of Drug Science and Technology, University of Turin, Turin, Italy,
3Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany, 4 Septomics
Research Center, Jena University Hospital, Jena, Germany, 5Department of Operative Intensive Care and Intermediate Care,
RWTH University Hospital Aachen, Aachen, Germany
Sepsis is one of the most prevalent diseases in the world. The development of cardiac
dysfunction in sepsis results in an increase of mortality. It is known that Bruton’s
tyrosine kinase (BTK) plays a role in toll-like receptor signaling and NLRP3 inflammasome
activation, two key components in the pathophysiology of sepsis and sepsis-associated
cardiac dysfunction. In this study we investigated whether pharmacological inhibition
of BTK (ibrutinib 30 mg/kg and acalabrutinib 3 mg/kg) attenuates sepsis associated
cardiac dysfunction in mice. 10-week old male C57BL/6 mice underwent CLP or
sham surgery. One hour after surgery mice received either vehicle (5% DMSO + 30%
cyclodextrin i.v.), ibrutinib (30 mg/kg i.v.), or acalabrutinib (3 mg/kg i.v.). Mice also
received antibiotics and an analgesic at 6 and 18 h. After 24 h, cardiac function was
assessed by echocardiography in vivo. Cardiac tissue underwent western blot analysis
to determine the activation of BTK, NLRP3 inflammasome and NF-κB pathway. Serum
analysis of 33 cytokines was conducted by a multiplex assay. When compared to
sham-operated animals, mice subjected to CLP demonstrated a significant reduction
in ejection fraction (EF), fractional shortening (FS), and fractional area change (FAC).
The cardiac tissue from CLP mice showed significant increases of BTK, NF-κB, and
NLRP3 inflammasome activation. CLP animals resulted in a significant increase of serum
cytokines and chemokines (TNF-α, IL-6, IFN-γ, KC, eotaxin-1, eotaxin-2, IL-10, IL-4,
CXCL10, and CXCL11). Delayed administration of ibrutinib and acalabrutinib attenuated
the decline of EF, FS, and FAC caused by CLP and also reduced the activation of
BTK, NF-κB, and NLRP3 inflammasome. Both ibrutinib and acalabrutinib significantly
suppressed the release of cytokines and chemokines. Our study revealed that delayed
intravenous administration of ibrutinib or acalabrutinib attenuated the cardiac dysfunction
associated with sepsis by inhibiting BTK, reducing NF-κB activation and the activation
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of the inflammasome. Cytokines associated with sepsis were significantly reduced by
both BTK inhibitors. Acalabrutinib is found to be more potent than ibrutinib and could
potentially prove to be a novel therapeutic in sepsis. Thus, the FDA-approved BTK
inhibitors ibrutinib and acalabrutinib may be repurposed for the use in sepsis.
Keywords: Bruton’s tyrosine kinase (BTK), sepsis, cardiac dysfunction, ibrutinib, acalabrutinib, NLRP3, NF-κB,
mice
INTRODUCTION
Sepsis is a life-threatening organ dysfunction caused by a
dysregulated host response to an infection (1), which affects
approximately 30 million people worldwide (2). In the UK,
sepsis is the second leading cause of death with 36,000–
64,000 patients dying each year (3) costing the NHS £2.5
billion annually (4). The development of cardiac dysfunction
affects 40% of septic patients (5) and is associated with
an increased mortality rate of 70–90% in comparison to
20% mortality in patients who do not present with cardiac
dysfunction (6). However, the mechanisms that underlie this
cardiac dysfunction are not well-known. Evidence suggests
that multiple factors contribute to the pathophysiology
of the cardiac dysfunction associated with sepsis. These
include the activation of NF-κB and NLRP3 leading to
excessive formation of e.g., IL-1 and TNF-α (7, 8). There are
currently no drugs for the specific treatment of the cardiac
dysfunction (or indeed the multiple organ dysfunction)
associated with sepsis that specifically target NF-κB and the
NLRP3 inflammasome.
Bruton’s tyrosine kinase (BTK) plays a role in innate immunity
and is a critical component in the development of B cells
(9). The FDA has approved the use of the irreversible BTK
inhibitors ibrutinib (first generation) in chronic lymphatic
leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom
macroglobulinemia (WM), and graft vs. host disease (10) and
acalabrutinib (more selective, second generation) in MCL (11).
Ibrutinib is also approved by the EMA for the treatment of
CLL, MCL, and WM (12), whereas acalabrutinib has received
an orphan designation for CCL, MCL, and lymphoplasmacytic
lymphoma (13–15). During sepsis, bacterial LPS stimulates TLR4
and BTK is directly involved in the activation of this signaling
pathway. Specifically, BTK binds to the TIR domain of TLR4
and its adaptor molecules (also found in other TLR’s) MyD88
and Mal, and results in downstream activation of NF-κB and
the generation of proinflammatory cytokines (16). BTK also
regulates the assembly and, hence, activation of the NLRP3
inflammasome by binding to the ASC component (17, 18).
Inhibition of BTK by BTK inhibitors reduces NF-κB activation
and the formation of NF-κB-dependent cytokines in murine
models of arthritis (19).
Given the importance of TLRs and NLRP3 in the
pathophysiology of sepsis, we hypothesized that BTK inhibitors,
such as ibrutinib or acalabrutinib, may attenuate the cardiac
dysfunction in a murine model of polymicrobial sepsis.
Additionally, we set out to investigate the potential effects of
BTK inhibition on (a) the activation of NF-κB and NLRP3 in the
heart, and (b) the serum levels of key, pro- and anti-inflammatory
cytokines and chemokines.
METHODS
Ethical Statement
The Animal Welfare Ethics Review Board of Queen Mary
University of London approved all experiments in accordance
with the Home Office guidance on the operation of Animals
(Scientific Procedure Act, 1986) published by Her Majesty’s
Stationary Office, and the Guide for the Care and Use of
Laboratory Animals of the National Research Council. Work
was conducted under U.K. home office project license number
PC5F29685. All in vivo experiments are reported in accordance
to ARRIVE guidelines (20).
Animals
This study was carried out on 40 10-week-oldmale C57BL/6mice
(Charles River Laboratories UK Ltd., Kent, UK) weighing 25–30 g
and kept under standard laboratory conditions. Six mice were
housed together (in each cage) with access to a chow diet and
water ad libitum. They were subjected to a 12-h light and dark
cycle with a temperature maintained at 19–23◦C.
Drugs
Ibrutinib and acalabrutinib were purchased from Selleck
Chemicals. Stock solutions were made in DMSO 5% and
cyclodextrin 30% (vehicle).
Murine Model of Polymicrobial Sepsis
Caused by Cecum Ligation and Puncture
(CLP)
Mice were randomized to undergo either sham operation, CLP
+ vehicle (5% DMSO + 30% cyclodextrin), CLP + ibrutinib
(30 mg/kg), or CLP + acalabrutinib (3 mg/kg). Before surgery,
mice were injected with buprenorphine (0.05 mg/kg, i.p.). Mice
were initially anesthetized by isoflurane (3 L/min) and oxygen
(1 L/min) in an anesthetic chamber and maintained with
isoflurane (2 L/min) and oxygen (1 L/min) via a face mask.
Temperature was monitored via a rectal probe and kept at
37◦C by a homeothermic mat. Veet R© hair removal cream was
used to remove the fur from the abdomen of the mouse and
skin was then cleaned with 70% ethanol. The abdomen was
opened with a 1.5 cm midline incision to expose the cecum.
The cecum was fully ligated below the ileocecal valve, and
a G-18 needle was used to puncture two holes in the top
and bottom of the cecum. A small amount of feces was then
squeezed out. The cecum was returned to the abdomen in its
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anatomical position and 5 ml/kg of saline was administered
into the abdomen before its closure. Saline (10 ml/kg s.c.)
was administered directly after surgery. One hour after CLP,
vehicle (5% DMSO + 30% cyclodextrin), ibrutinib (30 mg/kg),
or acalabrutinib (3 mg/kg) was administered intravenously. At
6 and 18 h after surgery, antibiotics (imipenem/cilastatin; 20
mg/kg dissolved in saline s.c.) and an analgesic (buprenorphine;
0.05 mg/kg i.p.) were administered. After 24 h, cardiac function
was assessed by echocardiography in vivo. Mice that underwent
sham surgery were not subjected to ligation or perforation of
the cecum but were otherwise treated the same way, 1 h after
surgery sham animals were treated with vehicle (5% DMSO +
30% cyclodextrin).
Renal Dysfunction Analysis
Renal dysfunction was analyzed in all mice. The mice were
anesthetized with isoflurane (3 L/min) and oxygen (1 L/min)
before being sacrificed. Cardiac puncture was performed
with a G25 needle and non-heparinized syringes to obtain
approximately 0.7ml of blood. The blood was immediately
decanted into 1.3ml serum gel tubes (Sarstedt, Nürnbrecht,
Germany). The heart and lungs were then removed. The blood
samples were centrifuged for 3min at 9,000 RPM to separate the
serum, where 100 µL of serum was pipetted into an aliquot and
snap frozen in liquid nitrogen and stored at −80◦C for further
analysis. The serum was then sent to an independent veterinary
testing laboratory (MRC Harwell Institute, Oxford, UK) to
blindly quantify serum urea and creatinine known markers of
renal dysfunction.
Echocardiography
At 24 h after CLP, cardiac function was assessed with a Vevo 3100
imaging system (VisualSonics, Toronto, Ontario, Canada). Mice
were fully sedated in an anesthetic chamber with isoflurane (3
L/min) and oxygen (1 L/min) and were then transferred to the
thermoregulatory platform in the supine position, where their
paws were taped on to the EKG leads. Anesthetic was maintained
throughout the entire procedure via a nosecone with isoflurane
(0.5–2.0 L/min) and oxygen (1 L/min). The fur on the chest was
removed by Veet R© hair removal cream and pre-warmed echo gel
was placed onto the shaven chest. The heart was then imaged
with the MX550D imaging probe. To measure the left ventricle
in B-mode the probe was placed along the long axis of the left
ventricle, and directed toward the right of the mouse, here we
measured percentage fractional area change (FAC%). The probe
was then rotated 90◦ to visualize the short axis in the M-mode
where the following parameters were measured: the percentage
ejection fraction (EF%) and fractional shortening (FS%).
Western Blot Analysis
Immunoblot analyses of cardiac tissue samples were carried out
using a semi-quantitative western blotting analysis. The antibody
used were: 1:1,000 rabbit anti-Ser176/180-IKKα/β, 1:1,000 rabbit
anti-total IKKα/β, 1:1,000 mouse anti-Ser32/36-IκBα, 1:1,000
mouse anti-total IκBα, 1:1,000 rabbit anti-NF-κB, 1:1,000 rabbit
anti-total BTK, 1:1,000 rabbit anti-Tyr1217 PLCγ, 1:1,000 rabbit
anti-total PLCγ (from Cell Signaling), 1:1,000 rabbit anti-Tyr223-
BTK, 1:5,000 rabbit anti NLRP3 inflammasome (from Abcam),
1:1,000 mouse anti-caspase 1 (p20) (fromAdipogen). The apex of
the heart was taken and homogenized in 1:10 of homogenization
buffer at 4◦C. Nuclear and cytosolic proteins were then
extracted as previously described (21) and concentrations were
quantified by bicinchoninic acid (BCA) protein assay (Thermo
Fisher Scientific Rockford, IL). Proteins were separated by
8% sodium dodecyl sulfate (SDS)-PAGE and transferred to
polyvinyldenedifluoride membranes. Membranes were blocked
in 10% milk solution with TBS-Tween and then incubated
with the primary antibody overnight at 4◦C. The next day the
secondary antibody was added for 30min at room temperature
and visualized using the ECL detection system. Tubulin and
histone 3 were used as loading control. The immunoreactive
bands were analyzed by the Bio-Rad Image Lab SoftwareTM 6.0.1
and results were normalized to the sham bands.
Multiplex Flow Immunoassay
The principle of multiplex flow immunoassay technology has
been reviewed previously (22, 23). Cytokines, chemokines and
a growth factor were determined in serum by Bio-Plex Pro
Mouse Chemokine 33-plex panel assay (Bio-Rad, Kabelsketal,
Germany). The cytokines IL-1ß,−2,−4,−6,−10,−16,
CCL1,−2,−3,−4,−5,−7,−11,−12,−17,−19,−20,−22,−24,−25,
−27, IFN-γ, TNF-α and the chemokines CX3CL1,
CXCL1,−2,−5,−10,−11,−12,−13,−16 and the growth factor
GM-CSF were measured according to the manufacturer’s
instructions. The assays were performed in one batch, with
samples randomly distributed. The lower detection limit was 3.2
pg/ml for all the analytes. Data were collected and analyzed using
a Bio-Plex R© 200 instrument equipped with Bio-Plex Manager
software (Bio-Rad).
Statistical Analysis
All data in text and figures are expressed as mean ±
standard error mean (SEM) of n observations. Measurements
obtained from the intervention, control and sham were analyzed
by one-way ANOVA followed by a Bonferroni’s post-hoc
test on GraphPad Prism 6.0 (GraphPad Software, Inc., La
Jolla, CA, USA). Correlations coefficients were determined
by Pearson’s correlation with P-values based on two-tailed
tests. Differences were considered to be statistically significant
when P < 0.05.
RESULTS
Ibrutinib or Acalabrutinib Attenuate the
Cardiac Dysfunction Caused by
CLP-sepsis
When compared to sham-operated animals, mice subjected to
CLP for 24 h (Figure 1A) demonstrated a significant reduction
in EF, FS, and FAC (P < 0.0001; Figures 1B–E) indicating
the development of systolic cardiac dysfunction. The observed
reduction in EF also negatively correlated with the rise of the
chemokines CXCL10 and CXCL11, both of which are well-
known biomarkers of left ventricular dysfunction (Figures 1F–I).
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FIGURE 1 | Ibrutinib or acalabrutinib attenuate the cardiac dysfunction caused by CLP-sepsis. Mice were randomly assigned to undergo CLP or sham surgery (n =
10). One hour later, mice were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). Cardiac function was
assessed 24 h after CLP surgery (n = 10 per group). (A) Illustration of the timelines of the CLP model. (B) Representative M-mode echocardiograms. (C) Ejection
fraction (%). (D) Fractional shortening (%). (E) Fractional area change (%). (F) CXCL10 serum concentration (pg/ml). (G) CXCL11 serum concentration (pg/ml). (H)
correlation of ejection fraction and CXCL10 serum concentration. (I) Correlation of ejection fraction and CXCL11 serum concentration. All data are expressed as mean
± SEM for n number of observations. A value of ****P < 0.0001, ***P < 0.001, **P < 0.01 was considered to be statistically significant when compared to the control
by one-way ANOVA followed by a Bonferroni’s post-hoc test. Correlations coefficients were determined by Pearson’s correlation with P-values based on
two-tailed tests.
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When compared to CLP mice treated with vehicle (control), the
administration of ibrutinib (30mg/kg) or acalabrutinib (3mg/kg)
at 1 h after CLP significantly attenuated the decline in EF, FS and
FAC caused by CLP (P < 0.01; Figures 1B–E). The rise in the
serum levels of the chemokines CXCL10 and CXCL11 caused
by CLP were also significantly reduced by either ibrutinib or
acalabrutinib (P< 0.05; Figures 1F–I). No significant differences
were observed in any of the cardiac parameters or cytokines
measured in CLP animals treated with either ibrutinib or
acalabrutinib (P > 0.05; Figures 1B–I). To gain a better insight
into the mechanism by which the two BTK-inhibitors reduce the
cardiac dysfunction associated with sepsis, we investigated the
effects of ibrutinib and acalabrutinib on (a) BTK-activation and
signaling, (b) NF-κB activation, and (c) NLRP3 inflammasome
assembly and activation (see below).
Ibrutinib or Acalabrutinib Attenuate the
Renal Dysfunction Caused by CLP-sepsis
Urea and creatinine were measured to study the effect of CLP
(in the absence and presence of BTK inhibitors) on kidney
function. When compared to sham, mice subjected to CLP
and treated with vehicle had a significant increase of urea and
creatinine, indicating kidney dysfunction (P < 0.0001; Figure 2).
Administration of ibrutinib (30 mg/kg) or acalabrutinib (3
mg/kg) to CLP mice significantly attenuated the rise in urea and
creatinine when compared to CLP mice treated with vehicle (P
FIGURE 2 | Ibrutinib or acalabrutinib attenuate the renal dysfunction caused by CLP-sepsis. Mice were randomly assigned to undergo CLP or sham surgery (n = 10).
One hour later, mice were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). At 24 h after CLP, blood
samples were collected for analyses (n = 10 per group). (A) Serum urea (mmol/L). (B) Serum creatinine (µmol/L). All data are expressed as mean ± SEM for n number
of observations. A value of ****P < 0.0001, ***P < 0.001, **P < 0.01 was considered to be statistically significant when compared to the control by one-way ANOVA
followed by a Bonferroni’s post-hoc test.
FIGURE 3 | Cardiac BTK is activated in CLP mice and reduced by ibrutinib or acalabrutinib. Mice were randomly assigned to undergo CLP or sham surgery. One hour
later, mice were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). At 24 h after CLP surgery, the
activation of BTK in the heart was analyzed by western blot analysis (n = 5 per group). Specifically, densitometric analysis of the bands is expressed as relative OD of
(A) phosphorylation of BTK at Tyr223 corrected for the corresponding total BTK and normalized using the related sham band. (B) Phosphorylation of PLCγ at Tyr1217
corrected for the corresponding total PLCγ. All data are expressed as mean ± SEM for n number of observations. A value of ****P < 0.0001 was considered to be
statistically significant when compared to the control by one-way ANOVA followed by a Bonferroni’s post-hoc test.
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< 0.01; Figure 2), without any significant difference between the
two treatment.
Cardiac BTK Is Activated in CLP Mice and
Reduced by Ibrutinib or Acalabrutinib
Using Western blot analysis, we investigated whether CLP-sepsis
leads to an activation of BTK in the heart. The activation of
BTK and the subsequent activation of BTK-signaling involves (a)
phosphorylation of BTK at Tyr223 and (b) the phosphorylation
of PLCγ at Tyr1217 by phosphorylated (activated) BTK as
the first step in the BTK-signaling cascade. When compared
to sham operated mice, CLP mice treated with vehicle
demonstrated significant increases in the phosphorylation of
cardiac BTK at Tyr223 and the phosphorylation of PLCγ
at Tyr1217, indicating that BTK is activated in septic hearts
(P < 0.0001; Figure 3A). Administration of ibrutinib (30
mg/kg) or acalabrutinib (3 mg/kg) in CLP mice resulted in
a significant decrease in the phosphorylation of cardiac BTK
at Tyr223 and the phosphorylation of PLCγ at Tyr1217 when
compared to CLP mice treated with vehicle (P < 0.0001;
Figure 3B) demonstrating that the doses of the two BTK
inhibitors used in our study caused a significant inhibition
of BTK-signaling in the heart. No significant differences were
observed in the degree of phosphorylation of cardiac BTK at
Tyr223 and the phosphorylation of PLCγ at Tyr1217 in CLP-
animals treated with either ibrutinib or acalabrutinib (P > 0.05;
Figures 3A,B).
Cardiac NF-κB Activation in CLP Mice Is
Reduced by Ibrutinib or Acalabrutinib
To understand the signaling mechanism associated with the
observed cardiac dysfunction, we investigated the effect of
BTK inhibition on the activation of key signaling pathways
of inflammation including pathways leading to the activation
of NF-κB. When compared to sham operated mice, CLP
mice treated with vehicle had significant increases in the
phosphorylation of IKKα/β at Ser176/180, the phosphorylation
of IκBα at Ser32/36 and the translocation of p65 to the
nucleus (P < 0.001; Figures 4A–C). When compared with
CLP mice treated with vehicle, treatment of CLP mice with
ibrutinib (30 mg/kg) or acalabrutinib (3 mg/kg) significantly
attenuated the increases in cardiac phosphorylation of IKKα/β
at Ser176/180 and IκBα at Ser32/36 and the nuclear translocation
of p65 (P < 0.0001; Figures 4A–C). No significant differences
were observed in the degree of phosphorylation of IKKα/β
at Ser176/180, the phosphorylation of IκBα at Ser32/36 and
the translocation of p65 to the nucleus in CLP animals
treated with either ibrutinib or acalabrutinib (P > 0.05;
Figures 4A–C).
Cardiac NLRP3 Activation in CLP Mice Is
Reduced by Ibrutinib or Acalabrutinib
We next assessed the potential involvement of NLRP3 in
the cardiac dysfunction of CLP mice. When compared to
sham operated mice, CLP-sepsis (vehicle-treatment) resulted
in the increased expression of the NLRP3 inflammasome
and cleavage of pro-caspase-1 to caspase-1 in the heart and
a rise in serum IL-1β (P < 0.0001; Figures 5A–C). When
compared to CLP mice treated with vehicle, treatment
of CLP mice with ibrutinib or acalabrutinib significantly
inhibited the expression of NLRP3, cleavage of pro-
caspase-1 to caspase-1 and the rise in IL-1β (P < 0.01;
Figures 5A–C), without any significant difference between the
two drug treatments.
Relationship Between BTK Activation and
Cardiac Dysfunction in CLP-sepsis
To address the question whether the degree of activation of
BTK correlates with alterations in cardiac function, we correlated
the degree of phosphorylation of BTK at Tyr223 (Figure 6A)
FIGURE 4 | Cardiac NF-κB activation in CLP mice is reduced by ibrutinib or acalabrutinib. Mice were randomly assigned to undergo CLP or sham surgery. One hour
later, mice were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). At 24 h cardiac tissue was collected
and signaling was assessed (n = 5 per group). Densitometric analysis of the bands is expressed as relative OD of (A) phosphorylation of IKKα/β at Ser176/180
corrected for the corresponding total IKKα/β and normalized using the related sham band. (B) Phosphorylation of IκBα at Ser32/36 corrected for the corresponding
total IκBα and normalized using the related sham band. (C) NF-κB p65 in both nucleus and cytosol and expressed as a ratio, normalized using the sham related
bands. All data are expressed as mean ± SEM for n number of observations. A value of ****P < 0.0001 was considered to be statistically significant when compared
to the control by one-way ANOVA followed by a Bonferroni’s post-hoc test.
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and the phosphorylation of PLCγ at Tyr1217 (Figure 6B) with
EF. We found a highly significant negative correlation between
the degree of BTK and PLCγ activation and the decline in
EF, strongly suggesting that BTK activation drives or precedes
the cardiac dysfunction associated with sepsis. To address the
question whether the degree of activation of BTK also correlates
with alterations in the activation of NF-κB, we correlated
the degree of phosphorylation of BTK at Tyr223 with the
translocation of p65 (Figure 6C) and the phosphorylation of
IKKα/β at Ser176/180 (Figure 6D). We found a highly significant
positive correlation between the degree of BTK activation
and the activation of NF-κB when measured as either the
translocation of p65 (Figure 6C) and the phosphorylation of
IKKα/β at Ser176/180 (Figure 6D). To address the question
whether the degree of activation of BTK also correlates with
alterations in the assembly and activation of the inflammasome,
we correlated the degree of phosphorylation of BTK at Tyr223
with either NLRP3 assembly (Figure 6E) or the activation of
caspase-1 (Figure 6F). We found a highly significant positive
correlation between the degree of BTK activation and the NLRP3
(Figure 6E) increased expression and the activation of caspase-1
(Figure 6F).
Systemic Inflammation in CLP Mice Is
Reduced by Ibrutinib or Acalabrutinib
We also studied the effect of CLP (in the absence and
presence of BTK inhibitors) on the systemic synthesis of
pro-inflammatory cytokines, anti-inflammatory cytokines
and pro-inflammatory chemokines. When compared to sham
operated mice, CLP (vehicle) resulted in a significant rise
in the serum levels of (a) the pro-inflammatory cytokines
TNF-α, IFN-γ, IL-6; (b) the anti-inflammatory cytokines
IL-4 and IL-10, and (c) the pro-inflammatory chemokines
KC/CXCL1, eotaxin-1/CCL11, eotaxin-2/CCL24 (P <
0.05; Figures 7A–H). The sepsis-induced increase in these
cytokines and chemokines was significantly attenuated
by both BTK inhibitors, the only exception being IL-6,
which was not significantly reduced by ibrutinib but a
FIGURE 5 | Cardiac NLRP3 activation in CLP mice is reduced by ibrutinib or acalabrutinib. Mice were randomly assigned to undergo CLP or sham surgery. One hour
later, mice were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). At 24 h after CLP surgery, the
assembly and activation of NLRP3 in the heart was analyzed by western blot analysis (n = 5 per group). Specifically, densitometric analysis of the bands is expressed
as relative OD of (A) NLRP3 activation, corrected against tubulin and normalized using the sham related bands. (B) Pro-caspase-1 against activated caspase-1 and
normalized using the sham related bands. (C) IL-1β serum concentration analyzed by multiplex assay (n = 8). All data are expressed as mean ± SEM for n number of
observations. A value of ****P < 0.0001, **P < 0.01 was considered to be statistically significant when compared to the control by one-way ANOVA followed by a
Bonferroni’s post-hoc test.
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FIGURE 6 | Relationship between BTK activation and cardiac dysfunction in CLP-sepsis. Correlation data to show (A) ejection fraction (%) vs. phosphorylation of BTK
at Tyr223. (B) ejection fraction (%) vs. of PLCγ at Tyr1217. (C) Phosphorylation of BTK at Tyr223 vs. NF-κB p65. (D) Phosphorylation of BTK at Tyr223 vs.
phosphorylation of IKKα/β atSer176/180. (E) Phosphorylation of BTK at Tyr223 vs. NLRP3. (F) Phosphorylation of BTK at Tyr223 vs. activated/pro-caspase-1. Data
was analyzed by the Pearson correlation coefficient test to calculate the r value and a two tailed T-test for significance.
trend in reduction was observed. No significant differences
were observed in the levels of cytokines or chemokines in
CLP animals treated with either ibrutinib or acalabrutinib
(P > 0.05; Figures 7A–H).
The data of all other cytokines/chemokines/growth
factors that we measured in all groups are provided in
Supplementary Figure 1.
DISCUSSION
We show here, for the first time, that administration of
two structurally different BTK inhibitors (ibrutinib and
acalabrutinib) both ameliorate the cardiac dysfunction
(measured as decline in EF, FS, or FAC by echocardiography)
caused by CLP-sepsis. The observed decline in EF also
Frontiers in Immunology | www.frontiersin.org 8 September 2019 | Volume 10 | Article 2129
O’Riordan et al. Bruton’s Tyrosine Kinase and Sepsis
FIGURE 7 | Systemic inflammation in CLP mice is reduced by ibrutinib or acalabrutinib. Mice were randomly assigned to undergo CLP or sham surgery. One hour
later, mice were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). At 24 h after CLP, blood samples were
collected, and the serum concentration of cytokines and chemokines were measured by a multiplex assay (n = 8 per group). (A) TNF-α serum concentration (pg/ml).
(B) IL-6 serum concentration (pg/ml). (C) IFN-γ serum concentration (pg/ml). (D) KC/CXCL1 serum concentration (pg/ml). (E) Eotaxin-1/CCL11 serum concentration
(pg/ml). (F) Eotaxin-2/CCL24 serum concentration (pg/ml). (G) IL-10 serum concentration (pg/ml). (H) IL-4 serum concentration (pg/ml). All data are expressed as
mean ± SEM for n number of observations. Correlations coefficients were determined by Pearson’s correlation with P-values based on two-tailed tests a value of ****P
< 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05 was considered to be statistically significant.
was associated with a significant increase in the serum
levels of two, well-known biomarkers of left ventricular
dysfunction, namely CXCL10 and CXCL11 (24–26). Most
notably, ibrutinib or acalabrutinib also attenuated the
rises in CXCL10 and CXCL11 caused by CLP-sepsis.
In addition, ibrutinib or acalabrutinib also reduced the
renal dysfunction (measured as increase in serum urea
or creatinine) caused by CLP-sepsis. Thus, both BTK
inhibitors reduced the cardiac and renal dysfunction caused
by sepsis.
What, then, is the mechanism by which ibrutinib or
acalabrutinib reduce the cardiac (renal) dysfunction caused by
sepsis? Ibrutinib is a potent BTK inhibitor, but not very specific
(as it also inhibits a multitude of other kinases), which is
approved by the FDA and the EMA for the use in CLL, MCL, and
WM. Acalabrutinib is a potent, but highly specific BTK inhibitor:
At a (relatively high) concentration of 1µM, acalabrutinib
strongly inhibited only the following 5 kinases: BTK, Bmx, ErbB4,
RIPK2, and TEC, while the same concentration of ibrutinib
inhibited 35 kinases. It should be noted that the doses of
acalabrutinib and ibrutinib that we used in our study in the
mouse resulted in a similar, ∼70%, inhibition of BTK activity
in septic hearts. We, therefore, propose that inhibition of BTK
activity explains the observed beneficial effects of ibrutinib or
acalabrutinib in sepsis. The activation of BTK and the subsequent
activation of BTK signaling involves (a) phosphorylation of BTK
at Tyr223 and (b) the phosphorylation of PLCγ at Tyr1217 by
phosphorylated (activated) BTK as the first step in the BTK
signaling cascade (27). We report here that sepsis results in
significant increases in the phosphorylation of cardiac BTK at
Tyr223 and the phosphorylation of PLCγ at Tyr1217, indicating
that BTK is activated in septic hearts. Most notably, the activation
of BTK negatively correlated with EF indicating that activation of
BTK is associated with the cardiac dysfunction in sepsis. Indeed,
inhibition of BTK activity with ibrutinib or acalabrutinib in the
heart of septic animals reduces the cardiac dysfunction in sepsis
suggesting that activation of BTK plays a pivotal role in the
pathophysiology of the cardiac dysfunction in sepsis.
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What are the mechanisms by which the activation of BTK
(in the heart) leads to cardiac dysfunction in sepsis? There
is good evidence that (a) the activation of BTK precedes the
activation of NF-κB (16), and (b) the activation of NF-κB plays
an important role in the cardiac dysfunction in sepsis (28, 29).
Specifically, inhibition of the activity of NF-κB attenuates the
cardiac dysfunction in sepsis (30, 31). We report here, for the first
time, that (a) activation of BTK is associated activation of NF-κB
in septic hearts, and (b) inhibition of BTK activity with ibrutinib
or acalabrutinib reduces both the activation of NF-κB in septic
hearts and the cardiac dysfunction caused by sepsis. Thus, we
propose that inhibition of the activation of NF-κB contributes to
the observed beneficial effects of the BTK inhibitors ibrutinib and
acalabrutinib in sepsis. When challenging BTK KO-mice with
LPS, Gabhann and colleagues observed reduced (i) activation of
NF-κB p65, (ii) Akt phosphorylation, and (iii) M1 polarization of
macrophages (32).
Activation of NF-κB drives the formation of a number of pro-
and anti-inflammatory cytokines and chemokines. We report
here that CLP-sepsis leads to a significant increase in the serum
levels of the pro-inflammatory cytokines TNF-α, IL-6, IFN-γ,
anti-inflammatory cytokines IL-10, IL-4 and the chemokines
KC/CXCL1, eotaxin-1/CCL11, eotaxin-2/CCL24, all of which
importantly contribute to the local and systemic inflammation
and organ injury associated with sepsis (33). Most notably,
we see the powerful pro-inflammatory cytokine TNF-α to be
ameliorated by both BTK inhibitors. TNF-α has been implicated
in murine models of sepsis and in humans with sepsis. TNF-α
acts in an autocrine and paracrinemanner leading tomacrophage
production and activation, resulting in the release of other
proinflammatory cytokines such as IL-6 and IL-8 (34, 35).
Similarly, there is also good evidence that activation of BTK
plays a crucial role in the assembly and activation of the
NLRP3 inflammasome (17, 18). The activation of the NLRP3
inflammasome has been suggested to play a role in the cardiac
dysfunction (36) and the pathophysiology of sepsis (37). Others
have reported that inhibition of the assembly and activation of
NLRP3 inflammasome protects against microbial sepsis (37).
We report here for the first time that (a) activation of BTK is
associated with the activation of the NLRP3 inflammasome in
septic hearts, and (b) inhibition of BTK activity with ibrutinib
and acalabrutinib reduces both the assembly and subsequent
activation of the NLRP3 inflammasome in septic hearts (and the
cardiac dysfunction caused by sepsis). Thus, we propose that
inhibition of the activation of theNLRP3 inflammasomemay also
contribute to the observed beneficial effects of the BTK inhibitors
ibrutinib and acalabrutinib in sepsis.
Activation of the NLRP3 inflammasome drives the formation
of IL-1β and IL-18, both of which play an important role in the
systemic inflammation and/or organ dysfunction in sepsis (38).
Specifically, inhibition of caspase-1 results in an inhibition of IL-
18 and IL-1β secretion, which, in turn, attenuated the cardiac
dysfunction caused by myocardial ischemia (39). The role of the
inflammasome in the pathophysiology of sepsis, however, is still
controversial: For example, survival was similar in wild-type and
caspase-1/11 knockout mice with sepsis, while the neutralization
of IL-1 and IL-18 reduced mortality in endotoxemia (38). Here
we show that BTK inhibition results in reduced serum levels
of IL-1β, and this was associated with an improvement of
cardiac function.
The evaluation of the efficacy of the BTK inhibitors used in our
study depends on the assumption that the development of organ
dysfunction (and specifically cardiac and renal dysfunction)
correlates with outcome. There is good evidence that the
occurrence of cardiac and/or renal dysfunction correlates
positively with an increase in mortality in patients with sepsis (6).
We have, however, not investigated the effects of BTK inhibition
on survival in animals with sepsis due to ethical reasons. It would
be useful to confirm whether inhibition of BTK activity does,
indeed, improve survival in longer models of sepsis (rather than
the very acute model employed here).
In addition to inhibiting BTK, ibrutinib and acalabrutinib also
strongly inhibit four other kinases. To ensure that inhibition
of BTK, indeed, accounts for the inhibition of NF-kB and the
inflammasome and ultimately the observed beneficial effects in
sepsis, it would be useful to repeat our study in BTK knockout
mice. Interestingly, of the kinases which are strongly inhibited
by ibrutinib and acalabrutinib, expression of ErbB4 (rather than
its activation) may play a role in the cardiac dysfunction and
cognitive impairment associated with sepsis (40). In contrast,
RIP2 kinase is unlikely to play a significant role in sepsis, as
the CLP-induced septic peritonitis was similar in RIP2 knockout
mice and their wild-type litter mates (41).
CONCLUSIONS
There are currently no specific treatments, which reduce the
cardiac dysfunction or, indeed, mortality in sepsis. Our data
shows for the first time that two commercially available
BTK inhibitors, ibrutinib or acalabrutinib, attenuate the CLP-
induced cardiac dysfunction through inhibition of the activation
of BTK/NF-κB and/or the NLRP3 inflammasome, which in
turn reduces the formation of a number of chemokines and
cytokines including TNF-α. Notably, no significant qualitative
or quantitative differences were found with two, chemically
distinct BTK-inhibitors suggesting that the observed beneficial
effects of both compounds in experimental sepsis are likely
to be a drug class related effect. Thus, BTK inhibitors are
FDA-approved drugs that maybe repurposed for the use in
sepsis, but also for other diseases associated with either local or
systemic inflammation.
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